個別化医療の市場規模、シェア、成長分析、製品別、用途別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

世界の個別化医療の市場規模は、2022年に5,120億米ドルとなり、2023年の5,703億7,000万米ドルから2031年までには1兆3,528億1,000万米ドルに成長し、予測期間（2024年～2031年）のCAGRは11.40％で成長する見通しです。

世界の個別化医療市場は、個々の患者に合わせた治療を提供するための遺伝子技術の統合によって牽引されています。ヒトのゲノムはそれぞれユニークであるため、個別化医療は、特にがんに対して特定の診断と治療を提供することを目的としています。腫瘍学が依然として主要な焦点である一方で、遺伝子技術の利用可能性の高まりは、非腫瘍学アプリケーションの需要にも拍車をかけています。遺伝子技術は二桁成長を遂げており、投資の増加が進歩を後押ししています。これにより、アルツハイマー病やパーキンソン病などの希少疾患の治療における個別化医療に新たな可能性が生まれています。ヘルスケアへの導入は歴史的に遅れているものの、医療予算の増加や製薬会社と政府機関との協力関係の強化により、今後数年間で個別化医療の導入が加速すると予想されます。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次・一次情報源
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主要な市場の考察

• 主要な成功要因
• 競合の程度
• 主要な投資機会
• 市場のエコシステム
• 価格分析
• バリューチェーン分析
• 特許分析
• ケーススタディ分析
• 技術分析

個別化医療市場：製品別

• 市場概要
• 個別化医療検査
  • 遺伝子検査
  • DTC検査
  • その他
• 個別化医療の治療
  • 医薬品
  • 医療機器
  • その他
• 個別化医療のケア
  • 遠隔医療
  • 医療情報技術
• 個別化された栄養と健康
  • 小売栄養
  • 補完代替医療

個別化医療市場：用途別

• 市場概要
• 腫瘍学
• 神経学
• 心臓病学
• 抗ウィルス薬
• 精神医学
• 免疫学
• その他

個別化医療市場：エンドユーザー別

• 市場概要
• 病院・臨床ケア
• 診断会社・検査施設
• 学術研究機関・調査室
• 契約調査機関
• バイオ・健康情報科学企業
• その他

個別化医療市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主要な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Roche Holding AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• AstraZeneca PLC（United Kingdom）
• Gilead Sciences, Inc.（USA）
• Amgen Inc.（USA）
• Siemens Healthineers（Germany）
• Guardant Health, Inc.（USA）
• Exact Sciences Corporation（USA）
• EMD Serono, Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• QIAGEN N.V.（Netherlands）
• Myriad Genetics, Inc.（USA）
• AbbVie Inc.（USA）
• Takeda Pharmaceutical Company（Japan）
• Caris Life Sciences, Inc.（US）
• MDxHealth SA（Belgium）
• Personalis, Inc.（US）
• Freenome Holdings, Inc.（US）
• Haplogen, Inc.（US）
• Molecular Partners AG（Switzerland）
• SOPHiA GENETICS SA（Switzerland）
• NantHealth, Inc.（US）
• Zymeworks Inc.（Canada）
• Celerion（US）

Global Personalized Medicine Market size was valued at USD 512 billion in 2022 and is poised to grow from USD 570.37 billion in 2023 to USD 1352.81 billion by 2031, growing at a CAGR of 11.40% during the forecast period (2024-2031).

The global Personalized Medicines Market is driven by the integration of genetic technology to deliver tailored treatments for individual patients. As each human genome is unique, personalized medicine aims to provide specific diagnoses and treatments, particularly for cancer. While oncology remains a major focus, the rising availability of genetic technology is spurring demand for non-oncology applications as well. Genetic technology is experiencing double-digit growth, with increasing investment propelling advancements. This has opened new possibilities for personalized medicine in treating rare diseases, including Alzheimer's and Parkinson's. Despite the historically slow adoption in healthcare, growing healthcare budgets and increased collaborations between pharmaceutical companies and government agencies are expected to accelerate the adoption of personalized medicine in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Personalized Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Personalized Medicine Market Segmental Analysis

Global Personalized Medicine Market is segmented by Product, Application, End Users, and region. Based on Product, the market is segmented into Personalized Medicine Testing (Genetic Testing, DTC Testing, Others), Personalized Medicine Therapeutics (Pharmaceuticals, Medical Devices, Others), Personalized Medical Care (Telemedicine, Health Information Technology), Personalized Nutrition & Wellness (Retail Nutrition, Complementary & Alternative Medicine). Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Antiviral, Psychiatry, Immunology, and Others. Based on End Users, the market is segmented into Hospitals And Clinical Care, Diagnostic Companies and Testing Facilities, Academic Research Institutes and Research Laboratories, Contract Research Organizations, Bio and Health Informatics Companies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Personalized Medicine Market

The rapid advancement of genetic technology is significantly influencing the healthcare and pharmaceutical industries, driving the demand for personalized medicines. With the genetic technology market valued at over USD 5 billion and anticipated to grow at a compound annual growth rate (CAGR) of more than 20% throughout the forecast period, the sector is attracting increasing investments. This growth is expected to enhance the availability, accessibility, and demand for personalized medicines, paving the way for more tailored and effective treatments. As genetic innovations continue to evolve, the integration of these technologies into personalized medicine is set to revolutionize healthcare delivery, further accelerating market expansion.

Restraints in the Global Personalized Medicine Market

One of the key restraints for the global Personalized Medicines Market is the slow adoption of new technologies within the healthcare industry. The sector is typically conservative in integrating advanced innovations like AI and genetic engineering, largely due to stringent regulations. Regulatory bodies impose strict guidelines on the use of these technologies in healthcare applications, and authorities are often hesitant to approve their widespread adoption until they are fully confident in their safety and effectiveness. This cautious approach significantly delays the implementation of cutting-edge technologies in personalized medicine, hindering market growth and innovation in the field.

Market Trends of the Global Personalized Medicine Market

A significant trend in the global Personalized Medicines Market is the increase in healthcare budgets across both developed and developing economies, a shift that has gained momentum in the post-pandemic era. While stagnant healthcare budgets had been a concern for many years, governments have notably boosted funding for healthcare, which is directly fueling research and development (R&D) in alternative treatments and personalized medicines. This rise in healthcare expenditure is improving access to personalized medicine for patients who require tailored treatments and can afford them, thereby driving market growth and expanding patient access to innovative therapeutic options.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Pricing Analysis
• Value Chain Analysis
• Patent Analysis
• Case Study Analysis
• Technology Analysis

Personalized Medicines Market by Product

• Market Overview
• Personalized Medicine Testing
  • Genetic Testing
  • DTC Testing
  • Others
• Personalized Medicine Therapeutics
  • Pharmaceuticals
  • Medical Devices
  • Others
• Personalized Medical Care
  • Telemedicine
  • Health Information Technology
• Personalized Nutrition & Wellness
  • Retail Nutrition
  • Complementary & Alternative Medicine

Personalized Medicines Market by Application

• Market Overview
• Oncology
• Neurology
• Cardiology
• Antiviral
• Psychiatry
• Immunology
• Others

Personalized Medicines Market by End Users

• Market Overview
• Hospitals And Clinical Care
• Diagnostic Companies and Testing Facilities
• Academic Research Institutes and Research Laboratories
• Contract Research Organizations
• Bio And Health Informatics Companies
• Others

Personalized Medicines Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Serono, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MDxHealth SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Personalis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freenome Holdings, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haplogen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Molecular Partners AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SOPHiA GENETICS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantHealth, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celerion (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments